Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 7/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243564 | 1.00 | MAOB (0.45) | MAOBMAPTL3MBTL1CTSSCTSL | |
| SCHEMBL6318573 | 0.83 | ITGB3 (0.52) | MAOBMAPTL3MBTL1CTSSCTSL | |
| SCHEMBL2966788 | 0.82 | CA12 (0.42) | MAPTCTSSCTSLCTSKCTSB | |
| SCHEMBL5965532 | 0.82 | CA12 (0.42) | MAPTCTSSCTSLCTSKCTSB | |
| SCHEMBL4593136 | 0.78 | HTT (0.47) | L3MBTL1CTSSCTSLSYK | |
| SCHEMBL220137 | 0.78 | HTT (0.47) | L3MBTL1CTSSCTSLSYK | |
| SCHEMBL6740295 | 0.78 | ALDH1A1 (0.43) | MAOBMAPTARHPGDMMP2 | |
| SCHEMBL24635967 | 0.76 | SYK (0.65) | MAPTCTSSCTSLCTSKCTSB | |
| SCHEMBL10402059 | 0.74 | SYK (0.47) | L3MBTL1CTSSCTSLCTSKCTSB | |
| SCHEMBL22775253 | 0.74 | SYK (0.55) | CTSSCTSLCTSKCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887881-B1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1192154-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| EP-1192154-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076999-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | MAOB 438/4885MAPT 4857/4885L3MBTL1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.